AUPH
NASDAQAurinia Pharmaceuticals Inc
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$15.68-0.12 (-0.76%)
01:30 PM07:45 PM
News · 26 weeks41+100%
2025-12-072026-05-31
Mix2190d
- SEC Filings8(38%)
- Insider7(33%)
- Other5(24%)
- Earnings1(5%)
Latest news
25 items- PRTANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC.SAN DIEGO, June 3, 2026 /CNW/ - Tang Capital Management, LLC announces that on June 2, 2026, it acquired 206,005 common shares (the "Common Shares") of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (the "Issuer") at a price of US $15.28 per share (approximately CAD $21.13 per share) for an aggregate purchase price of US $3.1 million (approximately CAD $4.35 million) by way of the public market. Immediately prior to the transaction, Tang Capital Management, LLC held 12,838,101 Common Shares of the Issuer. As a result of the purchase, Tang Capital Management, LLC beneficially owns 13,044,106 Common Shares, representing approximately 10.0% of the issued and outstanding Common Shares of the Issuer
- INSIDERChief Executive Officer Tang Kevin bought $12,455,227 worth of shares (814,606 units at $15.29) (SEC Form 4)4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
- INSIDERChief Legal Officer Robertson Stephen P. was granted 115,541 shares, increasing direct ownership by 23% to 621,402 units (SEC Form 4)4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
- INSIDERChief Financial Officer Hearne Michael S was granted 116,144 shares (SEC Form 4)4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
- INSIDERChief Operating Officer Cole Ryan was granted 116,144 shares (SEC Form 4)4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
- SECSEC Form 144 filed by Aurinia Pharmaceuticals Inc144 - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)
- SECSEC Form 144 filed by Aurinia Pharmaceuticals Inc144 - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)
- SECAurinia Pharmaceuticals Inc filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits8-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
- SECSEC Form 10-Q filed by Aurinia Pharmaceuticals Inc10-Q - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
- SECAurinia Pharmaceuticals Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
- PRAurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business ProgressAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced financial results for the three months ended March 31, 2026 and provided an update on recent business progress. Financial Results Total Revenue: For the three months ended March 31, 2026, total revenue was $77.7 million, up 24% from $62.5 million in the same period of 2025. Net Product Sales: For the three months ended March 31, 2026, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $73.6 million, up 23% from $60.0 million in the same period of 2025. License, Collaboration and Royalty Revenue: For the three months ended March 31, 2026,
- SECSEC Form DEF 14A filed by Aurinia Pharmaceuticals IncDEF 14A - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
- SECAurinia Pharmaceuticals Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
- INSIDERSEC Form 3 filed by new insider Cole Ryan3 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hearne Michael S3 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
- PRAurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value RightAurinia Pharmaceuticals Inc. (NASDAQ:AUPH), a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs, announced today it has entered into a definitive merger agreement (the "Merger Agreement") to acquire Kezar Life Sciences, Inc. (NASDAQ:KZR), a biotechnology company focusing on small-molecule therapeutics to treat unmet needs in autoimmunity and cancer, for $6.955 in cash per share of Kezar common stock, plus one non-transferable contingent value right ("CVR"), which represents the right to receive: (i) potential payments relating to the ongoing clinical development or disposition of zetomipzomib; (ii) certain proce
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Aurinia Pharmaceuticals IncSCHEDULE 13D/A - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)
- PRMKT Capital Applauds Aurinia Pharmaceuticals' Management TransitionBelieves the Board's Decision to Remove CEO Peter Greenleaf and Install Kevin Tang as CEO Validates Multi-Year Shareholder Campaign Commends New Leadership's Commitment to Shareholder Alignment Through Zero CEO Compensation Expects Aurinia to Enter New Chapter of Disciplined Capital Allocation and Value Creation MKT Capital Ltd. (together with its affiliates, "MKT Capital" or "we"), a significant long-term shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ("Aurinia" or the "Company"), today issued the following statement in response to the Company's announcement that Kevin Tang has been appointed Chief Executive Officer, effective immediately. Antoine Khalife, Founder of MKT
- SECAurinia Pharmaceuticals Inc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
- PRAurinia Announces Management TransitionAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) announced today that Kevin Tang, Aurinia's Chair of the Board, will succeed Peter Greenleaf as Chief Executive Officer. Peter will continue as a consultant to facilitate the transition. "Aurinia thanks Peter for his many contributions to the Company over his 7-year tenure and wishes him the best in his future endeavors," stated Mr. Tang. "Aurinia today is in an extremely strong position in no small part due to Peter's stewardship. LUPKYNIS is emerging as a standard therapy for lupus nephritis, and our lead pipeline product, aritinercept, is advancing quickly through clinical studies. I look forward to working closely with the Aurinia team on our
- INSIDERSVP, Chief Medical Officer Keenan Greg covered exercise/tax liability with 8,069 shares, decreasing direct ownership by 5% to 154,449 units (SEC Form 4)4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
- INSIDERDirector Tang Kevin bought $12,688,806 worth of shares (900,000 units at $14.10) (SEC Form 4)4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Aurinia Pharmaceuticals IncSCHEDULE 13D/A - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)
- INSIDERChief Operating Officer Donley Matthew Maxwell covered exercise/tax liability with 40,761 shares and was granted 58,160 shares, increasing direct ownership by 3% to 680,299 units (SEC Form 4)4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
- INSIDEREVP, General Counsel Robertson Stephen P. was granted 59,090 shares and covered exercise/tax liability with 36,525 shares, increasing direct ownership by 5% to 505,861 units (SEC Form 4)4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
AUPH FAQ
6 questionsWhat does Aurinia Pharmaceuticals Inc do?
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.Where does AUPH stock trade?
Aurinia Pharmaceuticals Inc (AUPH) is listed on NASDAQ.What sector and industry is AUPH in?
Aurinia Pharmaceuticals Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about AUPH?
Aurinia Pharmaceuticals Inc has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Market Perform with a $1600.00 price target on 2025-12-03. Recent price targets range from $1500.00 to $2700.00.What companies are similar to AUPH?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare AUPH side-by-side with any of them on Quantisnow.How can I track AUPH on Quantisnow?
Quantisnow aggregates Aurinia Pharmaceuticals Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AUPH to receive live email and push alerts on every new disclosure.